Porragas-Paseiro Hector S, Guntupalli Saketh, Xiong Jessie, Greenwood Ashley
University of Colorado School of Medicine, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, United States.
University of Colorado School of Medicine, Department of Pathology, United States.
Gynecol Oncol Rep. 2023 Mar 11;49:101160. doi: 10.1016/j.gore.2023.101160. eCollection 2023 Oct.
Primary clear cell adenocarcinoma of the vagina represents a rare form of cancer historically correlated with in-utero diethylstibestrol (DES) exposure. Mainstay treatment modalities include surgery, radiation, and chemotherapy. There has been a growing interest in immunotherapy in the field of oncology. KEYNOTE 826 demonstrated that patients with persistent, recurrent, or metastatic cervical cancer including patients who had adenocarcinoma showed improved progression and overall survival by the addition Pembrolizumab to chemotherapy plus or minus bevacizumab. To date, there are no documented cases using pembrolizumab as adjuvant treatment for active or recurrent vaginal clear cell adenocarcinoma. We present a case of a young patient with recurrent vaginal clear cell carcinoma who showed a complete and durable response to Pembrolizumab.
原发性阴道透明细胞腺癌是一种罕见的癌症形式，历史上与子宫内己烯雌酚（DES）暴露有关。主要治疗方式包括手术、放疗和化疗。肿瘤学领域对免疫疗法的兴趣日益浓厚。KEYNOTE 826试验表明，对于持续性、复发性或转移性宫颈癌患者，包括腺癌患者，在化疗基础上加用或不加用贝伐单抗并联合帕博利珠单抗可改善疾病进展和总生存期。迄今为止，尚无使用帕博利珠单抗作为活动性或复发性阴道透明细胞腺癌辅助治疗的文献记载病例。我们报告一例复发性阴道透明细胞癌年轻患者，该患者对帕博利珠单抗表现出完全且持久的反应。
